Fate Therapeutics (FATE) Tops Q2 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. HOOD
9. INTC
10. JBLU

Go back to Fate Therapeutics (FATE) Tops Q2 EPS by 7c

Fate Therapeutics Reports Second Quarter 2014 Financial Results

August 12, 2014 4:01 PM EDT

First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment

PROMPT and PROVIDE Studies of PROHEMA in Pediatric Patients to Initiate in 2H14

SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq: FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today reported financial results for the second quarter ended June 30, 2014 and announced that an independent Data Monitoring Committee (iDMC), following its first scheduled... More